secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001193125-22-218018
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences reports Q2 net loss $25.1M; cash runway into Q2 2024; SGT-003 IND on track
--------------------------------------------------------------------------------

- Net loss $25.1M in Q2 2022 vs $18.7M in Q2 2021; collaboration revenue $6.2M (up from $3.6M).
- Cash and investments $162.9M as of June 30, 2022; estimated runway into Q2 2024.
- Transition to transient transfection manufacturing for SGT-001; expects to continue dosing patients in 2023.
- Next-gen candidate SGT-003 on track for mid-2023 IND submission; capsid shows improved muscle tropism vs AAV9.
- Long-term data from IGNITE DMD trial of SGT-001 expected in early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522218018/0001193125-22-218018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522218018/d385975d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-218018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer